Long-Term Evaluation of HIV Antigen and Antibodies to p24 and gp41 in Patients with Hemophilia
- 29 October 1987
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 317 (18), 1114-1121
- https://doi.org/10.1056/nejm198710293171804
Abstract
To investigate the relation between human immunodeficiency virus (HIV) antigenemia and clinical manifestations of HIV infections, we studied 96 patients with hemophilia who were positive for HIV antibody, for a median of 34 months. Every 4 to 10 months a clinical and laboratory examination was performed and serum samples were tested for three HIV markers: HIV antigen, antibody to p24, and antibody to gp41. Twenty-two subjects (23 percent) were found to be positive for HIV antigen: 8 were positive upon entry and remained so (Group 1), and 14 became positive during the study, 4 to 26 months after HIV antibody appeared (seroconversion), 13 of whom remained positive for HIV antigen (Group 2). Most subjects positive for HIV antigen had low or undetectable titers of antibody to p24, whereas the antibody titer to gp41 remained high. In Group 2, patients with low p24 antibody titers had further decreases in their titers before or at the time HIV antigen appeared. Once present, HIV antigen persisted and tended to increase in concentration. In contrast to Group 3 (negative for HIV antigen, low anti-p24 titer) and 4 (negative for HIV antigen, high anti-p24 titer), the groups positive for HIV antigen had significantly higher incidences of acquired immunodeficiency syndrome (P = 0.05), immunodeficiency-related infections (P<0.001), and immune thrombocytopenia (P = 0.001), and had more severe disease as measured by the Walter Reed staging system (P<0.001). In this study, HIV antigen appeared to be a better predictive marker of HIVrelated complications than the absolute T4+ count. These results suggest that HIV antigenemia indicates a poor clinical prognosis. (N Engl J Med 1987; 317:1114–21.)Keywords
This publication has 23 references indexed in Scilit:
- HIV Isolation from Plasma of HIV-Infected PersonsNew England Journal of Medicine, 1987
- SEROLOGICAL MARKERS IN EARLY STAGES OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HAEMOPHILIACSThe Lancet, 1986
- Prevalence of HTLV-III/LAV Antibodies in Patients with Hemophilia and in Their Sexual Partners in FranceNew England Journal of Medicine, 1986
- EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN (HIV-Ag) IN SERUM AND CEREBROSPINAL FLUID DURING ACUTE AND CHRONIC INFECTIONThe Lancet, 1986
- HTLV-III serology in hemophilia: Relationship with immunologic abnormalitiesThe Journal of Pediatrics, 1986
- Three-Year Incidence of AIDS in Five Cohorts of HTLV-III-Infected Risk Group MembersScience, 1986
- The Walter Reed Staging Classification for HTLV-III/LAV InfectionNew England Journal of Medicine, 1986
- IMMUNOLOGICAL CHANGES IN LYMPHADENOPATHY VIRUS POSITIVE AND NEGATIVE SYMPTOMLESS MALE HOMOSEXUALS: TWO YEARS OF OBSERVATIONThe Lancet, 1985
- Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS PatientsScience, 1985
- Antibodies to HTLV-III in Swiss Patients with AIDS and Pre-AIDS and in Groups at Risk for AIDSNew England Journal of Medicine, 1985